Chargement en cours...
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours
AIMS: This phase I study evaluated the effects of the moderate cytochrome P450 (CYP) 3A inhibitor fluconazole and the strong CYP3A/P‐glycoprotein (P‐gp) inhibitor itraconazole on the pharmacokinetics of the investigational neural precursor cell expressed, developmentally downregulated 8 (NEDD8)‐acti...
Enregistré dans:
| Publié dans: | Br J Clin Pharmacol |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6595297/ https://ncbi.nlm.nih.gov/pubmed/30845347 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13915 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|